Related Experiment Video

Updated: Jun 27, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.4K

LAG-3 : recent developments in combinational therapies in cancer

Aude Chavanton1,2, Flavie Mialhe1,2, Jimena Abrey1,2

  • 1INSERM, UMR 1231, Laboratoire d'Excellence LipSTIC and « Equipe labellisée par la Ligue Nationale contre le Cancer », Dijon, France.

Cancer Science
|May 4, 2024
PubMed

Insights

New immunotherapies like lymphocyte activation gene 3 (LAG-3) inhibitors show promise for cancer patients resistant to current treatments. Combining LAG-3 inhibitors with other therapies may improve antitumor effects and broaden personalized medicine options.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Immune checkpoint inhibitors (ICIs) have transformed metastatic cancer care by targeting T cell inhibition.
  • Many patients exhibit resistance to current ICIs like anti-PD-1/PD-L1 and anti-CTLA-4.
  • Lymphocyte activation gene 3 (LAG-3) is an emerging immune checkpoint target with potential in overcoming cancer-associated immune resistance.

Purpose of the Study:

  • To review current knowledge on LAG-3 as an immunotherapeutic target.
  • To explore combination strategies involving LAG-3 inhibitors with existing and novel treatments.
  • To highlight potential for new therapeutic combinations to expand personalized cancer medicine.

Main Methods:

  • Literature review of preclinical and clinical studies on LAG-3 inhibitors.
  • Focus on combination therapies currently in Phase III clinical trials.
  • Analysis of innovative combinations in the preclinical phase.

Main Results:

  • LAG-3 inhibitors are being investigated in combination with chemotherapy, immunotherapy, radiotherapy, and adoptive cell therapies.
  • Several LAG-3 inhibitor combination therapies are advancing through Phase III clinical trials.
  • Preclinical studies are exploring novel LAG-3 based combination strategies.

Conclusions:

  • LAG-3 represents a promising target for overcoming resistance to cancer immunotherapy.
  • Combination therapies involving LAG-3 inhibitors have the potential to enhance antitumor efficacy.
  • Future research may lead to new therapeutic combinations, broadening personalized cancer treatment options.
Keywords:
LAG‐3TILsanticancer immune responsecombinational therapiesimmunotherapy

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

14.6K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
520
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
359